EUCTR2006-000715-19-FR进行中（未招募）1 期
A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain).
Sanofi Pasteur SA0 个研究点目标入组 230 人开始时间: 2006年3月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Subject vaccinated and who completed the Phase II VVL04 trial.
- •2) Informed consent form signed.
- •3) Subject able to attend all scheduled visits and to comply with all trial procedures.
- •4) Subject entitled to national social security.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
研究者
相似试验
进行中（未招募）
不适用
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-001373-97-LTAstraZeneca AB4,500
进行中（未招募）
不适用
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-001373-97-FIAstraZeneca AB4,500
进行中（未招募）
1 期
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSEUCTR2005-001373-97-GBAstraZeneca AB4,500
进行中（未招募）
不适用
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-001373-97-LVAstraZeneca AB4,500
进行中（未招募）
不适用
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSEUCTR2005-001373-97-EEAstraZeneca AB4,500